Learn more about the retrospective study comparing the effectiveness of gliclazide MR 60 mg versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled T2D, by using the UK Clinical Practice Research Datalink (CPRD) database.

Watch the video above, summarizing the study design, key results and conclusion.

Servier, in collaboration with the University of Leicester (UK), has published in the scientific journal Diabetes, Obesity and Metabolism the results of the first comparative real-world effectiveness and safety study on gliclazide MR  vs sitagliptin, in second-line treatment, following monotherapy with metformin, in patients with uncontrolled type 2 diabetes.